JBIO

SEC filing JBIO to Host June 1 Conference Call on JADE101 Phase 1 Interim Data Showing Every-12-Week Subcutaneous Dosing Potential

1d ago

News Jade Biosciences, Inc. GAAP EPS of -$0.57 misses by $0.09

25d ago

SEC filing JBIO Appoints Dr. Andrew King President, R&D; No Compensation Change

41d ago

SEC filing JBIO Reports $336M Cash Runway to 2028, Advances JADE101 Phase 1 Data Q2 2026, JADE201 RA Trial Q2 2026, JADE301 Phase 1 H1 2027

88d ago

News Brevan to Shut Golchin’s Hedge Fund as Focus Turns to Main Fund

125d ago

News H.C. Wainwright Initiates Jade Biosciences (JBIO) at Buy With $25 PT as JADE101 Eyes $926M Peak Revenue

134d ago

Short interest Short Interest

139d ago

News Jade Biosciences Announces $135 Million Private Placement

153d ago

Scanner Unusual volume (z=10.3)

160d ago

Scanner Unusual volume (z=10.3)

162d ago

Scanner Unusual volume (z=10.3)

163d ago

Scanner Unusual volume (z=10.3)

164d ago